Anagram Therapeutics, Inc.

Developing rationally designed orally delivered enzyme therapeutics for diseases caused by malabsorption syndromes and nutrient metabolism disorders.

[Anagram Therapeutics, Inc. @anagramtx]

Anagram Therapeutics Completes Dosing Study of ANG003, a Broad-Spectrum Oral Enzyme Replacement Therapy, in People with Cystic Fibrosis

https://t.co/6IwZ72gMIg

@CF_Foundation @NatPancFdn

[Anagram Therapeutics, Inc. @anagramtx]

Anagram Therapeutics is thrilled to announce Expansion of Joint Product Development Collaboration with ATUM to Accelerate Development of Orally Delivered Enzymes for Malabsorption and Nutrient Metabolism Disorders

https://t.co/pm1mCDEw7N

[Anagram Therapeutics, Inc. @anagramtx]

Anagram Therapeutics Announces Initiation of Clinical Study of ANG003 in People with Cystic Fibrosis

https://t.co/pm1mCDEw7N

[Anagram Therapeutics, Inc. @anagramtx]

Anagram welcomes Hugh, Pam and Sophia! What a great set of expertise to add to the Team! #anagramtx

https://t.co/pQmEmSHhGx

[Anagram Therapeutics, Inc. @anagramtx]

Anagram welcomes Dr. Preston Campbell to our Board of Directors!

[Anagram Therapeutics, Inc. @anagramtx]

Extremely grateful to the @CF_Foundation for their ongoing support to accelerate ANG003.

https://t.co/GFtMVjaBkE

[Anagram Therapeutics, Inc. @anagramtx]

It's launch day at Anagram Therapeutics!

https://t.co/x5O0C2zJLW